Beta Bionics (BBNX) Stock Price, News & Analysis

Company Overview

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Key Stats

• Today's Range: $17.43 to $18.50
• 50-Day Range: $12.53 to $18.33
• 52-Week Range: $8.89 to $24.50
• Volume: 343,873 shs
• Average Volume: 808,673 shs
• Market Capitalization: $796.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.56
• Consensus Rating: Moderate Buy

Beta Bionics Stock Analysis - MarketRank™

Beta Bionics scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Beta Bionics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Beta Bionics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Beta Bionics has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BBNX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beta Bionics does not currently pay a dividend.

Dividend Growth

Beta Bionics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for BBNX.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.54

News Sentiment

Beta Bionics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Beta Bionics this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Beta Bionics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beta Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $519,441.00 in company stock.

BBNX Stock Analysis - Frequently Asked Questions

How have BBNX shares performed this year?

Beta Bionics' stock was trading at $23.81 on January 1st, 2025. Since then, BBNX shares have decreased by 23.0% and is now trading at $18.33.

How were Beta Bionics' earnings last quarter?

Beta Bionics, Inc. (NASDAQ:BBNX) announced its earnings results on Tuesday, July, 29th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.12. The firm earned $23.24 million during the quarter, compared to analysts' expectations of $19.73 million.
Read the conference call transcript.

When did Beta Bionics IPO?

Beta Bionics (BBNX) raised $204 million in an initial public offering (IPO) on Thursday, January 30th 2025. The company issued 12,000,000 shares at $17.00 per share.

When did the company's lock-up period expire?

Beta Bionics's lock-up period expired on Tuesday, July 29th. Beta Bionics had issued 12,000,000 shares in its IPO on January 30th. The total size of the offering was $204,000,000 based on an initial share price of $17.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Who are Beta Bionics' major shareholders?

Beta Bionics' top institutional shareholders include Eventide Asset Management LLC (11.35%), Soleus Capital Management L.P. (8.79%), Sands Capital Alternatives LLC (8.21%) and Divisadero Street Capital Management LP (2.18%). Insiders that own company stock include Hadley Harbor Aggre Wellington, Mike Mensinger, Steven Jon Russell, Stephen Feider and Mark Hopman.
View institutional ownership trends.

How do I buy shares of Beta Bionics?

Shares of BBNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBNX
• Previous Symbol: NASDAQ:BBNX
• CIK: 1674632
• Web: N/A
• Phone: (949) 427-7785
• Fax: N/A
• Employees: 294
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Beta Bionics: $22.56
• High Price Target: $30.00
• Low Price Target: $16.00
• Potential Upside/Downside: +23.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.68
• Quick Ratio: 13.79

Sales & Book Value

• Annual Sales: $65.12 million
• Price / Sales: 12.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.94 per share
• Price / Book: 2.64

Miscellaneous

• Outstanding Shares: 43,470,000
• Free Float: N/A
• Market Cap: $796.81 million
• Optionable: N/A
• Beta: N/A